EAST RUTHERFORD, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Cambrex
(NYSE: CBM), a leading life sciences company, is pleased to announce that it
is providing a proprietary taste masking system to Novartis Consumer Health,
Inc. for a range of market leading over-the-counter (OTC) products. The
Cambrex proprietary system masks the negative taste associated with the active
pharmaceutical ingredients in these products.
"We are very proud to partner with Novartis Consumer Health to create and
provide an enabling taste masking system. Novartis is a world leader in
providing emerging drug delivery systems and packaging solutions to the
market," commented Gary L. Mossman, Cambrex Chief Operating Officer.
The Cambrex system uses technology that masks the unpleasant taste of many
active pharmaceutical ingredients in other drug delivery systems without the
use of sugar. Patients, particularly children and the elderly, who are unable
to use traditional dosing methods like hard-to-swallow tablets, can benefit
from alternative drug delivery technologies using taste masking.
About Cambrex
Cambrex is a global, diversified life science company dedicated to
providing high quality products and services to accelerate discovery,
development, and manufacturing of human therapeutics. The Company employs
approximately 1900 people worldwide. For more information, go to
http://www.cambrex.com.
Forward Looking Statements
This news release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 and Rule 3B-6 under
The Exchange Act, including, without limitation, statements regarding expected
performance, especially expectations with respect to sales, research and
development expenditures, earnings per share, capital expenditures,
acquisitions, divestitures, collaborations, or other expansion opportunities.
These statements may be identified by the fact that words such as "expects,"
"anticipates," "intends," "estimates," "believes" or similar expressions are
used in connection with any discussion of future financial and operating
performance. The forward-looking statements contained herein are based on
current plans and expectations and involve risks and uncertainties that could
cause actual outcomes and results to differ materially from current
expectations including but not limited to, global economic trends,
pharmaceutical outsourcing trends, competitive pricing or product
developments, government legislation and/or regulations (particularly
environmental issues), tax rate, technology, manufacturing and legal issues,
unfavorable results shipments, changes in foreign exchange rates, performance
of minority investments, un-collectable receivables, loss on disposition of
assets, cancellation or delays in renewal of contracts, and lack of suitable
raw materials or packaging materials. For further details and a discussion of
these and other risks and uncertainties, investors are cautioned to review the
Cambrex Annual Report on Form 10-K, including the Forward-Looking Statement
section therein, and other filings with the Securities and Exchange
Commission. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.
SOURCE Cambrex
 back to top
Related links:
http://www.cambrex.com
Company News On-Call:
http://www.prnewswire.com/comp/134219.html
CONTACT:
Steven Schneider, Manager Commercial
Development of Cambrex Pharma Business Unit, +1-201-689-0955,
steven.schneider@cambrex.com
|
